stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Shares outstanding
Rhythm Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $65.0M, up 6.54% from $61.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $69.0M. Over the past ten years it has ranged from $10.2M (fiscal 2015) to $65.0M (fiscal 2025) — the current reading is the highest in ten years. Rhythm Pharmaceuticals, Inc. ranks 218th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $65.0M | 6.54% |
| FY2024 | $61.0M | 5.76% |
| FY2023 | $57.7M | 10.65% |
| FY2022 | $52.1M | 5.08% |
| FY2021 | $49.6M | 12.40% |
| FY2020 | $44.1M | 21.15% |
| FY2019 | $36.4M | 17.48% |
| FY2018 | $31.0M | 133.68% |
| FY2017 | $13.3M | 30.13% |
| FY2016 | $10.2M | 0.00% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $69.0M | 0.66% |
| Jun 2026 | $68.6M | 0.91% |
| Mar 2026 | $68.0M | 4.60% |
| Dec 2025 | $65.0M | (1.93%) |
| 36 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $143.4M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| CORT Corcept Therapeutics Incorporated compare | $123.2M |
| ABVX Abivax SA Sponsored ADR compare | $79.6M |
| RYTM Rhythm Pharmaceuticals, Inc. | $69.0M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| AXSM Axsome Therapeutics, Inc. compare | $52.4M |
| PRAX Praxis Precision Medicines, Inc. compare | $29.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement